Old Drug Gets Green Light for Generic Copycats
Published Date: 5/8/2026
Notice
Summary
The FDA has decided that leucovorin calcium oral solution (60 mg per vial) wasn’t taken off the market because it was unsafe or ineffective. This means generic drug makers can now apply to sell their versions, speeding up access for patients. No extra safety worries or delays—just more options coming soon!
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Generic Access for Leucovorin 60 mg
The FDA determined that leucovorin calcium oral solution equivalent to 60 milligrams base per vial was not withdrawn from sale for reasons of safety or effectiveness. Because of this, abbreviated new drug applications (ANDAs) that refer to this listed drug may be approved if they meet all other legal and regulatory requirements, which can allow generic manufacturers to market equivalent products and increase patient access.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in